Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy

被引：159

作者：

Arya, Geetanjali ^{[1
]}

Vandana, Mallaredy ^{[1
]}

Acharya, Sarbari ^{[1
]}

Sahoo, Sanjeeb K. ^{[1
]}

机构：

[1] Inst Life Sci, Lab Nanomed, Bhubaneswar, Orissa, India

来源：

NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE | 2011年 / 7卷 / 06期

关键词：

Gemcitabine; Targeted drug delivery; Herceptin; Chitosan nanoparticles; Pancreatic cancer; DRUG-DELIVERY; H2AX PHOSPHORYLATION; INDUCED APOPTOSIS; DNA; MECHANISMS; OPTIMIZATION; BREAKS; CELLS;

D O I：

10.1016/j.nano.2011.03.009

中图分类号：

TB3 [工程材料学];

学科分类号：

082905 [生物质能源与材料];

摘要：

Currently, effective drug delivery in pancreatic cancer treatment is a major challenge. Nanomedicine plays an essential role by delivering anticancer drugs in a targeted manner to the malignant tumor cells, leading to increased efficacy by reducing the toxicity of anticancer drugs to normal, sensitive sites. This study investigated the preparation and characterization of a targeted system represented by Herceptin-conjugated gemcitabine-loaded chitosan nanoparticles (HER2-Gem-CS-NPs) for pancreatic cancer therapy. The targeted NPs displayed superior antiproliferative activity along with an enhanced S-phase arrest, leading to apoptosis in comparison with unconjugated gemcitabine-loaded nanoparticles and free gemcitabine due to higher cellular binding with eventual uptake and prolonged intracellular retention. Thus, HER2-Gem-CS-NPs are able to provide an efficient and targeted delivery of gemcitabine for pancreatic cancer treatment. From the Clinical Editor: This study investigated the preparation and characterization of a targeted drug delivery system consisting of Herceptin-conjugated gemcitabine-loaded chitosan nanoparticles for pancreatic cancer therapy. (C) 2011 Elsevier Inc. All rights reserved.

引用

页码：859 / 870

页数：12

共 41 条

[1]

Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy [J].

Acharya, Sarbari ;

Dilnawaz, Fahima ;

Sahoo, Sanjeeb K. .

BIOMATERIALS, 2009, 30 (29) :5737-5750

[2]

Recent advances on chitosan-based micro- and nanoparticles in drug delivery [J].

Agnihotri, SA ;

Mallikarjuna, NN ;

Aminabhavi, TM .

JOURNAL OF CONTROLLED RELEASE, 2004, 100 (01) :5-28

[3]

Endocytic mechanisms for targeted drug delivery [J].

Bareford, Lisa A. ;

Swaan, Peter W. .

ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (08) :748-758

[4]

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].

Burris, HA ;

Moore, MJ ;

Andersen, J ;

Green, MR ;

Rothenberg, ML ;

Madiano, MR ;

Cripps, MC ;

Portenoy, RK ;

Storniolo, AM ;

Tarassoff, P ;

Nelson, R ;

Dorr, FA ;

Stephens, CD ;

VanHoff, DD .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413

[5]

Chitosan and chitosan ethylene oxide propylene oxide block copolymer nanoparticles as novel carriers for proteins and vaccines [J].

Calvo, P ;

RemunanLopez, C ;

VilaJato, JL ;

Alonso, MJ .

PHARMACEUTICAL RESEARCH, 1997, 14 (10) :1431-1436

[6]

Ligand-based targeted therapy for cancer tissue [J].

Das, Manasi ;

Mohanty, Chandana ;

Sahoo, Sanjeeb K. .

EXPERT OPINION ON DRUG DELIVERY, 2009, 6 (03) :285-304

[7]

Characterization of nanoparticle uptake by endothelial cells [J].

Davda, J ;

Labhasetwar, V .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 233 (1-2) :51-59

[8]

Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy [J].

Dilnawaz, Fahima ;

Singh, Abhalaxmi ;

Mohanty, Chandana ;

Sahoo, Sanjeeb K. .

BIOMATERIALS, 2010, 31 (13) :3694-3706

[9]

H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation [J].

Ewald, Brett ;

Sampath, Deepa ;

Plunkett, William .

MOLECULAR CANCER THERAPEUTICS, 2007, 6 (04) :1239-1248

[10]

HUANG P, 1995, CANCER CHEMOTH PHARM, V36, P181, DOI 10.1007/BF00685844

← 1 2 3 4 5 →